Skip to main content

Moderna’s stock hit as flu-vaccine trial fails on one target. Meanwhile, China declares victory over COVID.

Moderna Inc.'s stock slid 5% Friday, after the COVID vaccine maker said a trial of a flu-vaccine candidate failed to meet one of its goals.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.